Incyte announced that the U.S. Food and Drug Administration has issued a complete response letter for ruxolitinib extended-release tablets, a JAK1/JAK2 inhibitor, for once-daily use in the treatment of certain types of myelofibrosis, polycythemia vera and graft-versus-host disease.
March 23, 2023
· 8 min read
